Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
AMPH Stock Forecast 2026-2027
$19.71
Current Price
$885.83M
Market Cap
Buy 0
Hold 7
Sell 0
Wall St Analyst Ratings
Distance to AMPH Price Targets
+52.2%
To High Target of $30.00
+9.1%
To Median Target of $21.50
-3.6%
To Low Target of $19.00
AMPH Price Momentum
-2.2%
1 Week Change
+16.8%
1 Month Change
-24.1%
1 Year Change
-26.4%
Year-to-Date Change
-36.9%
From 52W High of $31.26
+18.4%
From 52W Low of $16.65
📊 TOP ANALYST CALLS
Did AMPH Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Amphastar is one of their latest high-conviction picks.
Latest AMPH Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, AMPH has a neutral consensus with a median price target of $21.50 (ranging from $19.00 to $30.00). The overall analyst rating is Buy (6.0/10). Currently trading at $19.71, the median forecast implies a 9.1% upside. This outlook is supported by 0 Buy, 7 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AMPH Analyst Ratings
0
Buy
7
Hold
0
Sell
AMPH Price Target Range
Low
$19.00
Average
$21.50
High
$30.00
Current: $19.71
Latest AMPH Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AMPH.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 3, 2026 | Barclays | Glen Santangelo | Equal-Weight | Maintains | $20.00 |
| May 14, 2026 | Wells Fargo | Equal-Weight | Downgrade | $N/A | |
| May 11, 2026 | Piper Sandler | Neutral | Reiterates | $N/A | |
| May 8, 2026 | Needham | Hold | Downgrade | $N/A | |
| Apr 21, 2026 | Jefferies | Hold | Downgrade | $N/A | |
| Apr 8, 2026 | Barclays | Equal-Weight | Maintains | $N/A | |
| Feb 27, 2026 | Wells Fargo | Overweight | Maintains | $N/A | |
| Feb 27, 2026 | Needham | Buy | Maintains | $N/A | |
| Dec 9, 2025 | Barclays | Equal-Weight | Initiates | $N/A | |
| Nov 7, 2025 | Needham | Buy | Maintains | $N/A | |
| Oct 22, 2025 | Needham | Buy | Reiterates | $N/A | |
| Aug 26, 2025 | B of A Securities | Neutral | Maintains | $N/A | |
| Aug 12, 2025 | Needham | Buy | Upgrade | $N/A | |
| Aug 8, 2025 | Piper Sandler | Neutral | Maintains | $N/A | |
| May 12, 2025 | JP Morgan | Neutral | Downgrade | $N/A | |
| May 8, 2025 | Wells Fargo | Overweight | Maintains | $N/A | |
| Apr 10, 2025 | Needham | Hold | Reiterates | $N/A | |
| Mar 21, 2025 | Piper Sandler | Neutral | Maintains | $N/A | |
| Feb 4, 2025 | Piper Sandler | Neutral | Downgrade | $N/A | |
| Nov 22, 2024 | Wells Fargo | Overweight | Initiates | $N/A |
Amphastar Pharmaceuticals Inc. (AMPH) Competitors
The following stocks are similar to Amphastar based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Amphastar Pharmaceuticals Inc. (AMPH) Financial Data
Amphastar Pharmaceuticals Inc. has a market capitalization of $885.83M with a P/E ratio of 12.1x. The company generates $720.53M in trailing twelve-month revenue with a 11.0% profit margin.
Revenue growth is +0.4% quarter-over-quarter, while maintaining an operating margin of +8.0% and return on equity of +10.4%.
Valuation Metrics
Market Cap
$885.83M
Enterprise Value
$1.28B
P/E Ratio
12.1x
PEG Ratio
-0.2x
Price/Sales
1.2x
Growth & Margins
Revenue Growth (YoY)
+0.4%
Gross Margin
+41.1%
Operating Margin
+8.0%
Net Margin
+11.0%
EPS Growth
-74.6%
Financial Health
Cash/Price Ratio
+33.6%
Current Ratio
3.9x
Debt/Equity
88.7x
ROE
+10.4%
ROA
+5.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Amphastar Pharmaceuticals Inc. (AMPH) Business Model
About Amphastar Pharmaceuticals Inc.
What They Do
Develops and markets injectable and inhalation products.
Business Model
The company operates in the biopharmaceutical sector, generating revenue through the development, manufacturing, and marketing of both generic and proprietary medications. Amphastar Pharmaceuticals focuses on technically challenging products and serves various healthcare channels including hospitals, urgent care, and retail pharmacies, leveraging distribution partnerships with group purchasing organizations and wholesalers.
Additional Information
Founded in 1996 and headquartered in Rancho Cucamonga, California, Amphastar Pharmaceuticals operates cGMP-compliant facilities in the U.S., with additional presence in China and France. The company emphasizes innovation in drug delivery systems and aims to address critical medical needs in the specialty pharmaceutical sector.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
2,028
CEO
Dr. Yongfeng Zhang Ph.D.
Country
United States
IPO Year
2014
Website
www.amphastar.comAmphastar Pharmaceuticals Inc. (AMPH) Latest News & Analysis
Latest News
Quick Summary
Amphastar Pharmaceuticals (NASDAQ: AMPH) is shifting focus from complex generics to proprietary medicines and biosimilars, as stated by CFO Bill Peters at the East Coast IDEAS Conference.
Why It Matters
Amphastar's shift to proprietary medicines and biosimilars signals potential growth areas, impacting future revenue and market competitiveness, which could influence stock performance.
Source: MarketBeat
Market Sentiment:
Neutral
Quick Summary
Johnson Fistel, PLLP is investigating Amphastar Pharmaceuticals (NASDAQ: AMPH) and its executives for potential federal securities law violations related to investor losses.
Why It Matters
The investigation into Amphastar Pharmaceuticals could signal potential legal issues and financial instability, impacting share prices and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Amphastar Pharmaceuticals Sees Generic Atrovent Fueling 2026 Growth Despite BAQSIMI Drag
12 days ago
Quick Summary
Amphastar Pharmaceuticals expects mid- to high-single-digit revenue growth in 2026, driven by a new generic launch, Primatene Mist sales, and selected API sales in China.
Why It Matters
Amphastar's projected revenue growth signals stability and potential for profitability, driven by new products and international sales, which could positively influence stock performance.
Source: MarketBeat
Market Sentiment:
Positive
Quick Summary
Amphastar Pharmaceuticals (NASDAQ: AMPH) will present at the 2026 Jefferies Healthcare Conference on June 3, 2026, at 4:55 p.m. ET. Webcast available on their website.
Why It Matters
The presentation at the Jefferies Healthcare Conference could influence investor sentiment and stock performance for Amphastar Pharmaceuticals by highlighting company strategies and financial outlook.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Amphastar Pharmaceuticals (NASDAQ: AMPH) is addressing rebate and discount pressures on BAQSIMI while maintaining its full-year revenue outlook, as stated at the BofA Annual Healthcare Conference.
Why It Matters
Amphastar's actions to manage rebate pressures on BAQSIMI while maintaining revenue guidance indicate resilience, which may bolster investor confidence in its financial stability.
Source: MarketBeat
Market Sentiment:
Negative
Quick Summary
Amphastar Pharmaceuticals, Inc. (AMPH) presented at the Bank of America Global Healthcare Conference, highlighting its strategic initiatives and future outlook.
Why It Matters
Amphastar's presentation at a major healthcare conference can signal company growth potential, strategic direction, and market confidence, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About AMPH Stock
What is Amphastar Pharmaceuticals Inc.'s (AMPH) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, Amphastar Pharmaceuticals Inc. (AMPH) has a median price target of $21.50. The highest price target is $30.00 and the lowest is $19.00.
Is AMPH stock a good investment in 2026?
According to current analyst ratings, AMPH has 0 Buy ratings, 7 Hold ratings, and 0 Sell ratings. The stock is currently trading at $19.71. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AMPH stock?
Wall Street analysts predict AMPH stock could reach $21.50 in the next 12 months. This represents a 9.1% increase from the current price of $19.71. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Amphastar Pharmaceuticals Inc.'s business model?
The company operates in the biopharmaceutical sector, generating revenue through the development, manufacturing, and marketing of both generic and proprietary medications. Amphastar Pharmaceuticals focuses on technically challenging products and serves various healthcare channels including hospitals, urgent care, and retail pharmacies, leveraging distribution partnerships with group purchasing organizations and wholesalers.
What is the highest forecasted price for AMPH Amphastar Pharmaceuticals Inc.?
The highest price target for AMPH is $30.00 from at , which represents a 52.2% increase from the current price of $19.71.
What is the lowest forecasted price for AMPH Amphastar Pharmaceuticals Inc.?
Price targets from Wall Street analysts for AMPH are not currently available. The stock is trading at $19.71.
What is the overall AMPH consensus from analysts for Amphastar Pharmaceuticals Inc.?
The overall analyst consensus for AMPH is neutral. Out of 2 Wall Street analysts, 0 rate it as Buy, 7 as Hold, and 0 as Sell, with a median price target of $21.50.
How accurate are AMPH stock price projections?
Stock price projections, including those for Amphastar Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 16, 2026 2:07 AM UTC